CStone Pharmaceuticals (HKG:2616)
5.90
+0.34 (6.12%)
Sep 30, 2026, 4:08 PM HKT
CStone Pharmaceuticals Employees
CStone Pharmaceuticals had 102 employees as of June 30, 2026. The number of employees decreased by 34 or -25.00% since the number was reported on December 31, 2025.
Employees
102
Change
-34
Growth
-25.00%
Revenue / Employee
4.81M HKD
Profits / Employee
-4.74M HKD
Market Cap
9.39B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 102 | -34 | -25.00% |
| Dec 31, 2025 | 136 | 1 | 0.74% |
| Dec 31, 2024 | 135 | -95 | -41.30% |
| Dec 31, 2023 | 230 | -246 | -51.68% |
| Dec 31, 2022 | 476 | -135 | -22.09% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Shanghai Haohai Biological Technology | 1,999 |
| Ascentage Pharma Group International | 828 |
| Everest Medicines | 812 |
| Lepu Biopharma | 646 |
| Alphamab Oncology | 515 |
| Suzhou Ribo Life Science | 453 |
| HBM Holdings | 327 |
| Ascletis Pharma | 217 |
CStone Pharmaceuticals News
- 4 weeks ago - CStone Pharmaceuticals Earnings release: H1 2026 - Filings
- 4 weeks ago - CStone Pharmaceuticals Slides: H1 2026 - Filings
- 4 weeks ago - CStone Pharmaceuticals Quarterly report: H1 2026 - Filings
- 3 months ago - CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand - PRNewsWire
- 4 months ago - ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept - PRNewsWire
- 5 months ago - CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3) - PRNewsWire
- 6 months ago - CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0 - PRNewsWire
- 6 months ago - CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) - PRNewsWire